Company news
Theravance Biopharma, Inc. news in 2025
Theravance Biopharma, Inc.'s news releases, calls and decks from 2025, newest first.
Theravance Biopharma to Host Virtual KOL Investor Event to Review Ampreloxetine Phase 3 Clinical Development Program, Ahead of Topline Data in Q1 2026, on December 8, 2025
November 19, 2025
Theravance Biopharma to Participate in Upcoming Investor Conferences
November 18, 2025
Theravance Biopharma, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 9, 2025
Theravance Biopharma to Present Data on Ampreloxetine at the 36th International Symposium on The Autonomic Nervous System
October 28, 2025
Theravance Biopharma to Report Third Quarter 2025 Financial Results on November 10, 2025
October 26, 2025
Theravance Biopharma Launches Disease Education Campaign to Advance Scientific Understanding of Neurogenic Orthostatic Hypotension Due to Multiple System Atrophy
October 15, 2025
Theravance Biopharma to Present New Analyses Highlighting YUPELRI® (revefenacin) Outcomes in COPD at the 2025 CHEST Annual Meeting
October 13, 2025
Theravance Biopharma to Present at the H.C. Wainwright 27th Annual Global Investment Conference
September 1, 2025
Theravance Biopharma Completes Enrollment in Pivotal Phase 3 CYPRESS Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic Hypotension due to Multiple System Atrophy
August 24, 2025
Theravance Biopharma, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update
August 11, 2025
Theravance Biopharma to Report Second Quarter 2025 Financial Results on August 12, 2025
July 27, 2025
Theravance Biopharma to Participate in an Upcoming Investor Conference
July 22, 2025
Theravance Biopharma Announces Approval of YUPELRI® (revefenacin) by China's NMPA
June 25, 2025
Theravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 Million
June 1, 2025
Theravance Biopharma Announces Ampreloxetine Presentations at the International MSA Congress
May 8, 2025
Theravance Biopharma, Inc. Reports First Quarter 2025 Financial Results and Provides Corporate Update
May 7, 2025
Theravance to Present Analyses of Ampreloxetine and Neurogenic Orthostatic Hypotension at the 2025 International MSA Congress
April 27, 2025
Theravance Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025
April 23, 2025
Theravance Biopharma Presents Two New Ampreloxetine Analyses in Oral Session at the American Academy of Neurology 2025 Annual Meeting
April 6, 2025
Theravance Biopharma to Present New Ampreloxetine Analyses in Neurogenic Orthostatic Hypotension (nOH) at the 77th Annual Meeting of the American Academy of Neurology
March 26, 2025
Theravance Biopharma, Inc. Reports Record Fourth Quarter and Full Year 2024 Financial Results
February 25, 2025
Theravance Biopharma to Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025
February 11, 2025
Calls in 2025
- Theravance Biopharma (NASDAQ:TBPH) Q1 2026 Earnings Call
Dec 8, 2025
Transcript - Theravance Biopharma (NASDAQ:TBPH) Q3 2025 Earnings Call
Nov 10, 2025
Transcript - Theravance Biopharma (NASDAQ:TBPH) Q2 2025 Earnings Call
Aug 12, 2025
Transcript - Theravance Biopharma (NASDAQ:TBPH) Q1 2025 Earnings Call
May 8, 2025
Transcript - Theravance Biopharma (NASDAQ:TBPH) Q4 2024 Earnings Call
Feb 26, 2025
Transcript
Decks in 2025
- Investor Day (December 2025)
Investor day · 44 slides · Dec 8, 2025
- Q3 2025 Earnings Presentation
Earnings · 22 slides · Nov 10, 2025
- Q2 2025 Earnings Presentation
Earnings · 23 slides · Aug 12, 2025
- Q1 2025 Earnings Presentation
Earnings · 23 slides · May 8, 2025
- Technical Presentation (May 2025)
Technical · 18 slides · May 2025
- FY2024 Earnings Presentation
Earnings · 25 slides · Feb 26, 2025